Source comparison
Thymosin Alpha-1 MS Research Mechanism: Trial Design Comparison
J Neuroimmunol (2019) C57BL/6 EAE (MOG35-55) 1.6 mg/kg SC, 3×/week, 6 weeks Reduced CNS infiltration +68% vs baseline 40% vs control 1.9 vs 3.1 (day 28) Neurosci Lett (2019) SJL/J relapsing EAE (PLP139-151) 1.6 mg/kg SC, 3×/week, 8 weeks Lower relapse rate +72
This comparison does not assign a generated winner or score.
- J Neuroimmunol (2019)
- C57BL/6 EAE (MOG35-55)
- 1.6 mg/kg SC, 3×/week, 6 weeks
- Reduced CNS infiltration
- +68% vs baseline
- 40% vs control
- 1.9 vs 3.1 (day 28)
- Neurosci Lett (2019)
- SJL/J relapsing EAE (PLP139-151)
- 1.6 mg/kg SC, 3×/week, 8 weeks
- Lower relapse rate
- +72% vs baseline
- 38% vs control
- 1.8 vs 3.4 (day 40)
- J Neuroinflam (2020)
- C57BL/6 EAE (MOG35-55), prophylactic
- 2.0 mg/kg SC, 3×/week, 4 weeks pre-induction
- Delayed onset, reduced incidence
- +54% vs baseline
- 45% vs control
- Disease incidence 55% vs 90%
- Immunology (2021)
- Dark Agouti EAE (MBP68-86)
- 0.8 mg/kg SC, daily, 3 weeks
- Reduced IL-17 in CSF
- +41% vs baseline
- 29% vs control
- 2.3 vs 3.6 (day 21)
- Bottom Line
- Consistent efficacy across multiple EAE models. Treg expansion and Th17 suppression correlate directly with clinical benefit. Prophylactic dosing shows potential for delaying onset in high-risk populations. No tolerance observed across 8-week treatment periods.